secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0000950170-25-071839
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences Q1 net loss $27.5M; appoints Tony Gibney as CFO; Phase 3 CoMpass enrollment may complete by end 2025
--------------------------------------------------------------------------------

- Net loss $27.5M for Q1 2025 vs $19.7M in Q1 2024; R&D expenses rose to $23.3M from $17.1M.
- Cash and marketable securities $128.0M as of March 31, 2025; runway into second half of 2026.
- Appointed Tony Gibney as Chief Financial and Business Officer effective May 13, 2025; he brings 30+ years biotech and investment banking experience.
- Phase 3 CoMpass trial in early-stage choroidal melanoma actively enrolling; enrollment may complete as early as end 2025.
- First patient enrolled in multi-dose Phase 1b/2 trial of bel-sar in NMIBC; initial data at 3 months expected by year-end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000095017025071839/0000950170-25-071839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000095017025071839/aura-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-071839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer